GlassScriptPhysician profile
Roxanne Rea
NPI 1104177096
$4,482.67
in general payments reported to CMS, 2019-2025
35 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $824 · 2023: $779 · 2024: $985 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $748.28 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $424.13 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $207.77 | 2022-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.36 | 2021-2025 | Jardiance |
| Pfizer INC. | $178.03 | 2021-2025 | |
| Lilly USA, LLC | $177.66 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $175.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $150.96 | 2021-2023 | |
| Exact Sciences Corporation | $140.19 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $136.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $135.03 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.94 | 2022-2025 | Xifaxan, Trulance |
| Ultragenyx Pharmaceutical INC. | $110.21 | 2023-2024 | Crysvita |
| Dexcom, INC. | $109.17 | 2023-2025 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $91.19 | 2024-2025 | Unithroid |
| Sumitomo Pharma America, INC. | $81.19 | 2023-2025 | Gemtesa |
| Eisai INC. | $61.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.02 | 2021-2024 | Glassia, Trintellix |
| Merck Sharp & Dohme LLC | $56.22 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Alfasigma USA, INC. | $42.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $41.03 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $35.95 | 2021 | |
| Mylan Specialty L.P. | $35.76 | 2023-2024 | Yupelri |
| Medtronic, INC. | $27.35 | 2025 | Progrip |
| Viatris Specialty LLC | $24.59 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $23.29 | 2021 | |
| Impulse Dynamics (USA) INC. | $20.26 | 2023 | Optimizer |
| Lucid Diagnostics INC. | $17.39 | 2022 | |
| Inspire Medical Systems, INC. | $16.78 | 2025 | Inspire |
| Digestive Care, INC. | $15.85 | 2024 | Pertzye |
| Arbor Pharmaceuticals, INC. | $15.73 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Rea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.